{
    "title": "113_hr4709",
    "content": "The Act is titled the \"Ensuring Patient Access and Effective Drug Enforcement Act of 2014\" and pertains to the registration process under the Controlled Substances Act. The Controlled Substances Act is amended to define factors relevant to public health and safety and imminent danger to public health or safety. The Controlled Substances Act is amended to define factors relevant to public health and safety, including the distribution and dispensing of controlled substances outside of professional practice or in a manner that poses a risk of serious health consequences. Additionally, the Act allows for the submission of a corrective action plan before revocation or suspension. The Controlled Substances Act allows for an order to show cause with specific requirements for denial, revocation, or suspension proceedings, including the opportunity to submit a corrective action plan. Denial, revocation, or suspension proceedings may be discontinued or deferred for plan modification. Proceedings must follow specific guidelines and are independent of criminal prosecutions. Immediate suspension orders are exempt from these requirements. REPORT TO CONGRESS ON LAW ENFORCEMENT IMPACT ON PATIENT MEDICATION ACCESS. The Secretary of Health and Human Services, in consultation with other agencies, must submit a report to Congress identifying obstacles to patient access to controlled substances, issues with diversion, and ways to improve collaboration between law enforcement and the pharmaceutical industry. The report will incorporate feedback and recommendations from various stakeholders including patient groups, pharmacies, drug manufacturers, law enforcement agencies, healthcare providers, state attorneys general, and others. The House of Representatives passed the document on July 29, 2014. Karen L. Haas attested to it as the Clerk."
}